Table 2

Patient demography and pretreatment status

PatientSexAge (yr)Performance statusPrimary tumorPrior surgeryPrevious treatmentAssessable diseaseSerum CEA
1M380ColonHemicolectomyCtx: 5FU/faaStoma site20
IleostomyLiver
Inguinal node
2M420ColonHemicolectomyCtx: 5FU/faLiver10
Hemi-hepatectomy(CT portography)
3F630ColonHemicolectomyXRT: liverLiver581
Ctx: 5FU/fa
4M570RectumAnterior resectionCtx: 5FU/fa, MMCLung<3
5M310ColonSigmoid colectomyXRT: pelvisOmental mass<3
Ctx: 5FU/fa, 5FU/CDDPMalignant ascites
IFN-a
6F460AppendixAppendectomyCtx: 5FU/fa, 5FU/CDDPLiver<3
HemicolectomyOvary
7F421Sigmoid colonSigmoid colectomyCtx: 5FU/faPara-aortic nodes19
Small bowel resection
Hysterectomy
Ureteric stent
8F461ColonHemicolectomyCtx: 5FU/fa, 5FU/CDDPPara-aortic nodes<3
OopherectomyLung
Pelvic mass
9M470ColonLow anterior resectionCtx: 5FU/faLung155
Liver
10M751RectumAnterior resectionCtx: 5FU/fa, oral 5FU/faLiver419
  • a Ctx, chemotherapy; XRT, radiotherapy, 5FU, 5fluorouracil; fa, folinic acid; MMC, mitomycin C; CDDP, cisplatin.

  • b Reference ranges, CEA < 10 μg l−1.